263 related articles for article (PubMed ID: 23600703)
1. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
[TBL] [Abstract][Full Text] [Related]
2. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.
Bohlius J; Schmidlin K; Boué F; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Paparizos V; Miro JM; Obel N; Prins M; Chêne G; Egger M;
Blood; 2011 Jun; 117(23):6100-8. PubMed ID: 21368291
[TBL] [Abstract][Full Text] [Related]
3. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009.
Calabresi A; Ferraresi A; Festa A; Scarcella C; Donato F; Vassallo F; Limina R; Castelli F; Quiros-Roldan E;
HIV Med; 2013 Sep; 14(8):481-90. PubMed ID: 23560682
[TBL] [Abstract][Full Text] [Related]
4. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.
Kowalkowski MA; Mims MP; Amiran ES; Lulla P; Chiao EY
PLoS One; 2013; 8(10):e77409. PubMed ID: 24098586
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study.
Hoffmann C; Hentrich M; Gillor D; Behrens G; Jensen B; Stoehr A; Esser S; van Lunzen J; Krznaric I; Müller M; Oette M; Hensel M; Thoden J; Fätkenheuer G; Wyen C
HIV Med; 2015 Apr; 16(4):261-4. PubMed ID: 25252101
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
7. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
8. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
Lanoy E; Rosenberg PS; Fily F; Lascaux AS; Martinez V; Partisani M; Poizot-Martin I; Rouveix E; Engels EA; Costagliola D; Goedert JJ;
Blood; 2011 Jul; 118(1):44-9. PubMed ID: 21551234
[TBL] [Abstract][Full Text] [Related]
9. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
10. Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era.
Albini L; Calabresi A; Gotti D; Ferraresi A; Festa A; Donato F; Magoni M; Castelli F; Quiros-Roldan E
AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1097-104. PubMed ID: 23581483
[TBL] [Abstract][Full Text] [Related]
11. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
12. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.
Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Costagliola D; Grabar S;
Clin Infect Dis; 2013 Dec; 57(11):1638-47. PubMed ID: 23899679
[TBL] [Abstract][Full Text] [Related]
13. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk in people infected with human immunodeficiency virus in the United States.
Engels EA; Biggar RJ; Hall HI; Cross H; Crutchfield A; Finch JL; Grigg R; Hylton T; Pawlish KS; McNeel TS; Goedert JJ
Int J Cancer; 2008 Jul; 123(1):187-94. PubMed ID: 18435450
[TBL] [Abstract][Full Text] [Related]
18. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998.
Glaser SL; Clarke CA; Gulley ML; Craig FE; DiGiuseppe JA; Dorfman RF; Mann RB; Ambinder RF
Cancer; 2003 Jul; 98(2):300-9. PubMed ID: 12872349
[TBL] [Abstract][Full Text] [Related]
19. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.
Hleyhel M; Hleyhel M; Bouvier AM; Belot A; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S;
AIDS; 2014 Sep; 28(14):2109-18. PubMed ID: 25265077
[TBL] [Abstract][Full Text] [Related]
20. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
